EU/3/02/117: Orphan designation for the treatment of peritumoral oedema derived from brain tumours

Boswellia serrata

Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2006 on request of the sponsor.

On 21 October 2002, orphan designation (EU/3/02/117) was granted by the European Commission to Pharmasan GmbH, Germany, for boswellia serrata resin extract for the treatment of peritumoral oedema derived from brain tumours.

Key facts

Active substance
Boswellia serrata
Intended use
Treatment of peritumoral oedema derived from brain tumours
Orphan designation status
EU designation number
Date of designation
Pharmasan GmbH
Obere Hardtstrasse 18
79114 Freiburg
Telephone: +49 761 4909100
Telefax: +49 761 4909 125

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating